Codiak Biosciences

Codiak Biosciences is a biotechnology startup that was founded in 2015. The company is focused on developing exosome-based therapeutics, which constitute a new class of medicines with the potential to address a wide spectrum of diseases with high unmet medical need. Codiak leverages the biology of exosomes as natural intercellular transfer mechanisms and has created its proprietary engEx Platform to enhance the innate properties of exosomes. This platform enables the design, engineering, and manufacture of novel exosome therapeutic candidates. Codiak has built a robust pipeline of engineered exosomes aimed at treating a broad range of disease areas, including oncology, neuro-oncology, neurology, neuromuscular disease, and infectious disease. The startup has recently secured a significant $20.00MPost-IPO Equity investment on 12 September 2022. This funding is indicative of the growing interest in the potential of exosome-based therapeutics and bodes well for Codiak's future development and product commercialization efforts. As Codiak continues to advance its innovative therapies, it positions itself as a promising player in advancing treatments for various challenging diseases within the biopharmaceutical industry.